Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Lipide: Diagnostik und Therapie bei Diabetes mellitus

verfasst von: Thomas C. Wascher, Bernhard Paulweber, Hermann Toplak, Christoph H. Säly, Heinz Drexel, Bernhard Föger, Friedrich Hoppichler

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Hyper- und Dyslipidämie tragen zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Überzeugende Daten zeigen, dass durch die medikamentöse Therapie mit Statinen das kardiovaskuläre Risiko von Diabetikern senken kann. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz lipidsenkender Medikamente dar.
Fußnoten
1
Typ 1 Diabetes ohne zusätzliche Risikofaktoren oder Endorganerkrankung.
 
2
Typ 2 Diabetes sowie Typ 1 Diabetes mit zusätzlichen Risikofaktoren oder Endorganerkrankung.
 
Literatur
1.
Zurück zum Zitat European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidemias: the task force for the management of dyslipidemias. Eur Heart J. 2011;32:1769–818. CrossRefPubMed European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidemias: the task force for the management of dyslipidemias. Eur Heart J. 2011;32:1769–818. CrossRefPubMed
2.
Zurück zum Zitat Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, prediabetes, and cardiovascular disease developed in collaboration with the EASD: the task force on diabetes, prediabetes and cardiovascular disease. Eur Heart J. 2013;34:3035–87. CrossRefPubMed Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, prediabetes, and cardiovascular disease developed in collaboration with the EASD: the task force on diabetes, prediabetes and cardiovascular disease. Eur Heart J. 2013;34:3035–87. CrossRefPubMed
3.
Zurück zum Zitat Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 trials of statins. Lancet. 2005;366:1267–78. CrossRefPubMed Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 trials of statins. Lancet. 2005;366:1267–78. CrossRefPubMed
4.
Zurück zum Zitat Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25. CrossRef Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25. CrossRef
5.
Zurück zum Zitat Cholesterol Treatment Trialists Collaborators. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular diesease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90. CrossRef Cholesterol Treatment Trialists Collaborators. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular diesease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90. CrossRef
6.
Zurück zum Zitat Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8. CrossRefPubMed Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8. CrossRefPubMed
7.
Zurück zum Zitat Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapie after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. CrossRefPubMed Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapie after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. CrossRefPubMed
8.
Zurück zum Zitat Keach A, Simmes RJ, Barter B, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type-2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61. CrossRef Keach A, Simmes RJ, Barter B, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type-2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61. CrossRef
9.
Zurück zum Zitat The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes mellitus. N Engl J Med. 2010;362:1563–74. CrossRefPubMedCentral The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes mellitus. N Engl J Med. 2010;362:1563–74. CrossRefPubMedCentral
Metadaten
Titel
Lipide: Diagnostik und Therapie bei Diabetes mellitus
verfasst von
Thomas C. Wascher
Bernhard Paulweber
Hermann Toplak
Christoph H. Säly
Heinz Drexel
Bernhard Föger
Friedrich Hoppichler
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0933-1

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe